GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066413 | Liver | NAFLD | triglyceride metabolic process | 29/1882 | 100/18723 | 9.51e-08 | 7.62e-06 | 29 |
GO:00066392 | Liver | NAFLD | acylglycerol metabolic process | 32/1882 | 128/18723 | 8.82e-07 | 4.60e-05 | 32 |
GO:00066382 | Liver | NAFLD | neutral lipid metabolic process | 32/1882 | 129/18723 | 1.06e-06 | 5.35e-05 | 32 |
GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
GO:00194322 | Liver | NAFLD | triglyceride biosynthetic process | 13/1882 | 42/18723 | 1.60e-04 | 2.94e-03 | 13 |
GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
GO:00464601 | Liver | NAFLD | neutral lipid biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
GO:00464631 | Liver | NAFLD | acylglycerol biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
GO:000664111 | Liver | Cirrhotic | triglyceride metabolic process | 40/4634 | 100/18723 | 5.36e-04 | 4.23e-03 | 40 |
GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
GO:00066412 | Liver | HCC | triglyceride metabolic process | 59/7958 | 100/18723 | 6.35e-04 | 3.93e-03 | 59 |
GO:000663911 | Liver | HCC | acylglycerol metabolic process | 72/7958 | 128/18723 | 1.16e-03 | 6.54e-03 | 72 |
GO:000663811 | Liver | HCC | neutral lipid metabolic process | 72/7958 | 129/18723 | 1.54e-03 | 8.14e-03 | 72 |
GO:00194321 | Liver | HCC | triglyceride biosynthetic process | 26/7958 | 42/18723 | 8.76e-03 | 3.41e-02 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AGMO | SNV | Missense_Mutation | novel | c.289N>C | p.Tyr97His | p.Y97H | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | novel | c.779G>A | p.Gly260Asp | p.G260D | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | | c.1304N>A | p.Ser435Asn | p.S435N | Q6ZNB7 | protein_coding | tolerated(0.08) | benign(0.382) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | | c.475N>T | p.Ala159Ser | p.A159S | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | novel | c.650N>A | p.Thr217Asn | p.T217N | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | rs768857037 | c.38N>T | p.Ser13Phe | p.S13F | Q6ZNB7 | protein_coding | tolerated(0.13) | benign(0.017) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | novel | c.702N>C | p.Lys234Asn | p.K234N | Q6ZNB7 | protein_coding | deleterious(0) | possibly_damaging(0.887) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
AGMO | SNV | Missense_Mutation | rs751893917 | c.905N>T | p.Pro302Leu | p.P302L | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | rs746980089 | c.50N>A | p.Arg17His | p.R17H | Q6ZNB7 | protein_coding | deleterious(0.03) | possibly_damaging(0.583) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGMO | SNV | Missense_Mutation | novel | c.294T>G | p.Ile98Met | p.I98M | Q6ZNB7 | protein_coding | tolerated(0.08) | benign(0.066) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |